Helix BioPharma (HBP)
Helix BioPharma Debt to Equity Ratio: 0.00
- Accounts Payable
- Accounts Receivable
- Accruals Pro
- Altman Z-Score Pro
- Asset Utilization
- Beneish M-Score Pro
- Beta Pro
- Book Value
- Book Value per Share
- Capital Expenditures
- Cash Conversion Cycle Pro
- Cash Div. Payout Ratio TTM Pro
- Cash Financing
- Cash Financing TTM
- Cash Investing
- Cash Investing TTM
- Cash Operations
- Cash Operations TTM
- Cash and Equivalents
- Cash and ST Investments
- Current Ratio
- Days Inventory Outstanding Pro
- Days Payable Outstanding Pro
- Days Sales Outstanding Pro
- Debt to Equity Ratio
- Dividend
- Dividend Yield
- EBITDA Margin TTM Pro
- EBITDA TTM Pro
- EV / EBIT Pro
- EV / EBITDA Pro
- EV / Free Cash Flow Pro
- EV / Revenues Pro
- Earnings Per Share
- Earnings Per Share Growth
- Earnings Per Share TTM
- Earnings Yield
- Effective Tax Rate TTM Pro
- Enterprise Value
- Expenses
- Expenses TTM
- Free Cash Flow
- Free Cash Flow TTM
- Free Cash Flow Yield Pro
- Fundamental Score Pro
- Gross Profit Margin
- Gross Profit TTM
- Income from Cont. Ops Pro
- Interest Expense
- Interest Income
- Inventories
- KZ Index Pro
- Liabilities
- Long Term Debt
- Market Cap
- Net Income
- Net Income TTM
- Net PP&E
- Operating Earnings Yield Pro
- Operating Margin TTM Pro
- Operating PE Ratio Pro
- Other Comprehensive Income Pro
- PE 10 Pro
- PE Ratio
- PE Value Pro
- PEG Ratio
- PS Value Pro
- Payout Ratio TTM Pro
- Price
- Price / Book Value
- Price / Sales Ratio
- Price / Tangible Book Value Pro
- Profit Margin
- R&D Expense
- Receivables Turnover
- Retained Earnings
- Retained Earnings Growth
- Return on Assets
- Return on Equity
- Return on Invested Capital Pro
- Revenue Growth
- Revenue Per Share TTM
- Revenues
- Revenues TTM
- SG&A Expense
- Shareholders Equity
- Shares Outstanding
- Stock Buybacks
- Tangible Book Value Pro
- Tangible Book Value Per Share Pro
- Tangible Common Equity Ratio Pro
- Times Interest Earned TTM Pro
- Total Assets
- Total Return Price
- Valuation (Historical Mult.) Pro
- Valuation Percentage Pro
- Value Score Pro
- Accounts Payable
- Accounts Receivable
- Accruals Pro
- Altman Z-Score Pro
- Asset Utilization
- Beneish M-Score Pro
- Beta Pro
- Book Value
- Book Value per Share
- Capital Expenditures
- Cash Conversion Cycle Pro
- Cash Div. Payout Ratio TTM Pro
- Cash Financing
- Cash Financing TTM
- Cash Investing
- Cash Investing TTM
- Cash Operations
- Cash Operations TTM
- Cash and Equivalents
- Cash and ST Investments
- Current Ratio
- Days Inventory Outstanding Pro
- Days Payable Outstanding Pro
- Days Sales Outstanding Pro
- Debt to Equity Ratio
- Dividend
- Dividend Yield
- EBITDA Margin TTM Pro
- EBITDA TTM Pro
- EV / EBIT Pro
- EV / EBITDA Pro
- EV / Free Cash Flow Pro
- EV / Revenues Pro
- Earnings Per Share
- Earnings Per Share Growth
- Earnings Per Share TTM
- Earnings Yield
- Effective Tax Rate TTM Pro
- Enterprise Value
- Expenses
- Expenses TTM
- Free Cash Flow
- Free Cash Flow TTM
- Free Cash Flow Yield Pro
- Fundamental Score Pro
- Gross Profit Margin
- Gross Profit TTM
- Income from Cont. Ops Pro
- Interest Expense
- Interest Income
- Inventories
- KZ Index Pro
- Liabilities
- Long Term Debt
- Market Cap
- Net Income
- Net Income TTM
- Net PP&E
- Operating Earnings Yield Pro
- Operating Margin TTM Pro
- Operating PE Ratio Pro
- Other Comprehensive Income Pro
- PE 10 Pro
- PE Ratio
- PE Value Pro
- PEG Ratio
- PS Value Pro
- Payout Ratio TTM Pro
- Price
- Price / Book Value
- Price / Sales Ratio
- Price / Tangible Book Value Pro
- Profit Margin
- R&D Expense
- Receivables Turnover
- Retained Earnings
- Retained Earnings Growth
- Return on Assets
- Return on Equity
- Return on Invested Capital Pro
- Revenue Growth
- Revenue Per Share TTM
- Revenues
- Revenues TTM
- SG&A Expense
- Shareholders Equity
- Shares Outstanding
- Stock Buybacks
- Tangible Book Value Pro
- Tangible Book Value Per Share Pro
- Tangible Common Equity Ratio Pro
- Times Interest Earned TTM Pro
- Total Assets
- Total Return Price
- Valuation (Historical Mult.) Pro
- Valuation Percentage Pro
- Value Score Pro
Select a metric
Date range:
to
<Embed Chart>
Pro Save as Image
Pro Data Export
Copy the code below and paste
into the embed destination.
into the embed destination.
Attention
OK
HBP Debt to Equity Ratio Rankings
| Overall | 99th percentile | 1 of 4259 |
| Sector | 99th percentile | 1 of 476 in Healthcare |
| Industry | 98th percentile | 1 of 71 in Medical Appliances & Equipment |
HBP Debt to Equity Ratio Range, Past 5 Years
| Minimum | 0.00 | Jul 2007 |
| Maximum | 0.00 | Jul 2007 |
| Average | 0.00 |
About Debt to Equity Ratio
YCharts Calculation: Debt to Equity = (Long Term Debt + Current Portion of Long Term Debt) / Total Shareholders' Equity
The debt to equity ratio is a leverage ratio indicating the relative proportion of shareholders' equity and debt used to finance a company's assets. It reveals how a company has financed its assets. A low debt to equity ratio indicates lower risk because shareholder's have claims on a larger portion of the company's assets.
A high debt to equity ratio usually means that a company has been aggressive in financing growth with debt and often results in volatile earnings.
It is also known as Debt/Equity Ratio, Debt-Equity Ratio, and D/E Ratio.
Learn More
You may also be interested in these HBP related companies
HBP News
Helix BioPharma (HBP) Announces Court Approval of Shareholder Settlement
May 07, 5:48PM Street Insider
May 07, 5:48PM Street Insider
Helix BioPharma Corp. Updates Shareholders on Court Approval of Settlement
May 07, 5:41PM Marketwire
May 07, 5:41PM Marketwire
Helix BioPharma Corp. Reconstituted Board of Directors Provides Update to Shareholders
Apr 05, 5:50PM Marketwire
Apr 05, 5:50PM Marketwire
Helix BioPharma Corp. Updates Shareholders on Results From Annual General Meeting
Jan 30, 9:05PM Marketwire
Jan 30, 9:05PM Marketwire
Helix BioPharma (HBP) Reports Troubling Findings Following Shareholder Investigation
Jan 26, 6:50AM Street Insider
Jan 26, 6:50AM Street Insider
Special Committee of Helix BioPharma Corp. Provides Update to Shareholders
Jan 25, 8:08PM Marketwire
Jan 25, 8:08PM Marketwire
Helix BioPharma (HBP) Reports Institutional Shareholder Services Encourages Shareholders Vote for Management Nominees
Jan 23, 4:55PM Street Insider
Jan 23, 4:55PM Street Insider
Helix BioPharma Corp. Proposes New Board Slate for January 30, 2012 Annual General Meeting
Jan 07, 12:11AM Marketwire
Jan 07, 12:11AM Marketwire
Michael Burry Write ups from 2000 http://stks.co/1PaJ $CR $HBP $SPY $VCLK
about 175 days ago by valuewalk
about 175 days ago by valuewalk
The Special Committee of Helix BioPharma Corp. Provides Update to Shareholders
Dec 06, 11:12AM Marketwire
Dec 06, 11:12AM Marketwire
FDA Lifts Clinical Hold on Helix BioPharma (HBP) Topical Interferon Alpha-2b, Phase II/III IND
Nov 11, 6:53AM Street Insider
Nov 11, 6:53AM Street Insider
Helix BioPharma terminates agreement with ACM Alpha Consulting Management
Oct 21, 4:51AM FlyOnTheWall
Oct 21, 4:51AM FlyOnTheWall
Helix BioPharma Corp. Terminates Agreement With ACM Alpha Consulting Management Est.
Oct 20, 8:51PM Marketwire
Oct 20, 8:51PM Marketwire
Helix BioPharma Corp. Receives Shareholder Requisition to Hold Meeting to Elect Directors
Oct 18, 5:19PM Marketwire
Oct 18, 5:19PM Marketwire
Helix BioPharma (HBP) Files IND Response for Topical Interferon Phase II/III
Oct 13, 6:38AM Street Insider
Oct 13, 6:38AM Street Insider
Helix BioPharma receives approval for European Phase I/II clinical study
Jul 25, 6:41AM FlyOnTheWall
Jul 25, 6:41AM FlyOnTheWall
Recent Quotes
| Symbol | Price | Chg | Chg % | Market Cap |
|---|---|---|---|---|
| HBP | 1.52 | -0.08 | -5.00% | 102.17M |
| HBOS | 12.26 | -0.09 | -0.73% | |
| HBAN | 6.64 | +0.18 | +2.79% | 5.593B |
| HAYN | 54.43 | -0.18 | -0.33% | 671.16M |
| HAV | 8.85 | +0.00 | +0.00% | |
| HAUP | 1.19 | +0.01 | +1.28% | 11.89M |
| HAST | 2.12 | +0.00 | +0.00% | 17.77M |
| HAS | 35.53 | +0.62 | +1.78% | 4.491B |
| HARL | 17.99 | +0.10 | +0.56% | 66.74M |
| HAR | 41.61 | +1.02 | +2.51% | 2.849B |
